The Annex to Implementing Regulation (EU) 2021/17 is amended as follows:
in part A, entry 1 is replaced by the following:
‘1 | Change in the name or address of: | |
|
the marketing authorisation holder
The marketing authorisation holder shall remain the same legal entity. The marketing authorisation holder shall already be incorporated in the Union IT systems storing and providing organisational data. |
|
a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where specified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier.
The manufacturing or quality control site and all manufacturing operations shall remain the same.
The manufacturer or supplier shall already be incorporated in the Union IT systems storing and providing organisational data (not applicable for starting material and reagent manufacturers/suppliers).
|
an active substance master file (ASMF) holder
The manufacturing site and all manufacturing operations shall remain the same.
The ASMF holder shall already be incorporated in the Union IT systems storing and providing organisational data.
Updated “letter of access” to the Active Substance Master File.’
|
a manufacturer of a [novel] excipient (where specified in the dossier)
The manufacturing site and all manufacturing operations shall remain the same. |
|
a manufacturer or importer of the finished product (including batch release or quality control testing sites)
The manufacturing or quality control site and all manufacturing operations shall remain the same.
The manufacturer or supplier shall already be incorporated in the Union IT systems storing and providing organisational data.
part B is amended as follows:
entry 1 is replaced by the following:
‘1 | Change in the name or address of a supplier of a packaging component or of a device of the finished product (where mentioned in the dossier): |
The supplier shall already be incorporated in the Union IT systems storing and providing organisational data.
The manufacturing site shall remain the same.’
entry 3 is amended as follows:
point (a) is replaced by the following:
‘a) |
a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for importation, manufacturer responsible for batch release, site where batch control takes place, or supplier of (1) a starting material for an active substance, (2) a reagent or (3) an excipient (when mentioned in the dossier)
The deletion shall not be due to critical deficiencies concerning manufacturing.
There shall at least remain one site or manufacturer, as previously authorised, performing the same function as the one(s) concerned by the deletion.
There shall at least remain one site or manufacturer responsible for batch release within the European Union or the European Economic Area.’
point (i) is replaced by the following:
‘i) |
a component or components of the flavouring or colouring system
The change shall not have the potential to affect the identity, strength, quality, purity, potency, safety or effectiveness of the finished product.
For veterinary medicinal products for oral use, the change does not affect the uptake by target animal species.
No change in functional characteristics of the pharmaceutical form, e.g. disintegration time, dissolution profile.
Any minor adjustment to the formulation to maintain the total weight shall be made by an excipient which currently makes up a major part of the finished product formulation.
Stability studies have been started in line with conditions set out in the relevant guidelines, International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (ICH/VICH), Ph. Eur. etc., (with indication of batch numbers) and relevant stability parameters have been assessed in at least two pilot scale or industrial scale batches and at least 3 months satisfactory stability data are at the disposal of the applicant and the stability profile is similar to the currently registered situation. Assurance is given that these studies will be finalised and that data will be provided immediately to the competent authorities if outside specifications or potentially outside specifications at the end of the approved shelf life (with proposed action). In addition, where relevant, photo-stability testing shall be performed.’
entry 4 is replaced by the following:
‘4 | Change in the manufacturer of a starting material, reagent or intermediate used in the manufacturing process of the active substance or change in the manufacturer of the active substance where no Ph. Eur. CEP is part of the approved dossier: | | Amendment of the relevant section(s) of the dossier
|
change in a manufacturer (including relevant quality control testing sites) that is part of the same pharmaceutical group as the currently approved manufacturer
The change shall not be applicable to a sterile active substance or a biological or immunological substance.
The new manufacturer shall already be incorporated in the Union IT-systems storing and providing organisational data.
For starting materials and reagents the specifications (including in-process controls, methods of analysis of all materials), shall be identical to those already approved. For intermediates and active substance(s) the specifications (including in process controls, methods of analysis of all materials), method of preparation (including batch size) and detailed route of synthesis shall be identical to those already approved.
Where materials of human or animal origin are used in the process, the manufacturer does not use any new supplier for which assessment is required of viral safety or of compliance with the current Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products.
TSE data as appropriate.
Batch analysis data for at least two batches (minimum pilot scale).
Qualified person (QP) declaration.
|
changes to quality control testing arrangements for the active substance: replacement or addition of a site where batch control or testing of the active substance takes place
The change shall not be applicable to a sterile active substance or a biological or immunological substance.
The new manufacturer or site shall already be incorporated in the Union IT-system storing and providing organisational data.
Method transfer from the former to the new site shall have been successfully completed.
|
introduction of a new site of micronisation for the active substance
The change shall not be applicable to a sterile active substance or a biological or immunological substance.
The new manufacturer or site shall already be incorporated in the Union IT-systems storing and providing organisational data.
The change shall not provoke an adverse change in physico-chemical properties.
The particle size specification for the active substance and the corresponding analytical method shall remain the same.
Batch analysis data for at least two comparative batches (minimum pilot scale).
Qualified Person (QP) declaration.’
|
new storage site of Master Cell Bank or Working Cell Banks
No change shall be made to the storage conditions, the shelf-life and the specifications.
The new site shall already be incorporated in the Union IT-systems storing and providing organisational data.
entry 9 is replaced by the following:
‘9 | Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance: |
The change shall not be applicable to a biological or immunological substance.
The change shall not adversely affect the reproducibility of the process.
Changes to the manufacturing methods shall only be those necessitated by scale-up or downscaling, e.g. use of different-sized equipment.
Amendment of the relevant section(s) of the dossier.
Test results of at least two batches in accordance with the specifications for the proposed batch size.’
|
up to 10-fold increase compared to the originally approved batch size
The change shall not be applicable to a sterile active substance.
The active substance and all intermediates, reagents, catalysts or solvents shall still conform to the approved specifications.
|
downscaling down to 10-fold
The change shall not be the result of unexpected events arising during manufacture or because of stability concerns. |
|
more than 10-fold increase compared to the originally approved batch size
The change shall not be applicable to a sterile active substance.
The intermediates, reagents, catalysts or solvents used in the process shall remain the same.
The active substance and all intermediates, reagents, catalysts or solvents shall still conform to the approved specifications.
The change shall not provoke an adverse change in qualitative and quantitative impurity profile, or in physico-chemical properties of the active substance.
The change shall not refer to the restricted part of an ASMF.
entry 11 is amended as follows:
the introductory wording is replaced by the following:
‘11 | Change in the specification parameters or limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance or of the immediate packaging of the active substance: |
The change shall not result from unexpected events arising during manufacture or storage (e.g. new unqualified impurity or change in total impurity).
The change shall not be a consequence of any commitment from previous assessments to review specification limits (e.g. made during the procedure for the marketing authorisation application or a variation procedure in accordance with Article 62 of Regulation (EU) 2019/6) unless it has been previously assessed and agreed as part of a follow-up measure in a previous procedure under Regulation (EU) 2019/6.
"/> |
Amendment of the relevant section(s) of the dossier.
Comparative table of former and new specification parameters and limits.’
point (a) is replaced by the following:
‘a) |
tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance for all veterinary medicinal products including products subject to Official Control Authority Batch Release (OCABR);
The test procedure shall remain the same, or changes in the test procedure shall be minor.
The change shall be within the range of currently approved limits.’
point (b) is deleted
points (c) and (d) are replaced by the following:
‘c) |
tightening of specification limits of the immediate packaging of the active substance
The test procedure shall remain the same, or changes in the test procedure shall be minor.
The change shall be within the range of currently approved limits.
|
addition of a new specification parameter to the specification with its corresponding test method for an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance
The new test method shall not concern a novel non-standard technique or a standard technique used in a novel way.
The new test method shall not be a biological, immunological or immunochemical method, or a method using a biological reagent for a biological active substance, except if this method is a standard pharmacopoeial microbiological method.
The change shall not concern a genotoxic impurity.
If it involves the final active substance, other than for residual solvents which shall be in line with ICH/VICH limits, any new impurity control shall be in line with the Ph. Eur. or National Pharmacopoeia of a Member State.
Details of any new analytical method and validation data, where relevant.
Batch analysis data on two production batches (3 production batches for biologicals, unless otherwise justified) of the relevant substance for all specification parameters.
Where appropriate, comparative dissolution profile data for the finished product on at least one pilot batch containing the active substance complying with the current and proposed specification. For herbal veterinary medicinal products, comparative disintegration data may be acceptable.
Justification from the marketing authorisation holder (MAH) or ASMF Holder as appropriate of the new specification parameter and the limits.’
the following point (e) is added:
‘e) |
addition of a new specification parameter to the specification with its corresponding test method for the immediate packaging of the active substance
The new test method shall not concern a novel non-standard technique or a standard technique used in a novel way. |
Details of any new analytical method and validation data, where relevant.
Batch analysis data on two batches of the immediate packaging for all specification parameters.
Justification from the marketing authorisation holder or the ASMF Holder, as appropriate, of the new specification parameter and the limits.’
entry 12 is replaced by the following:
‘12 | Minor changes: | |
|
to an approved test procedure
for active substance or a starting material, reagent or intermediate used in the manufacturing process of the active substance;
for the finished product;
for an excipient
The test method shall not be a biological, immunological or immunochemical method, or a method using a biological reagent (does not include standard pharmacopoeial microbiological methods).
Appropriate validation studies shall have been performed in accordance with the relevant guidelines and show that the updated test procedure is at least equivalent to the former test procedure.
There shall be no changes of the total impurity limits; no new unqualified impurities shall be detected.
The method of analysis shall remain the same (e.g. a change in column length or temperature, but not a different type of column or method).
Amendment of the relevant section(s) of the dossier, including a description of the analytical methodology, a summary of validation data and revised specifications for impurities (if applicable).
Comparative validation results, or if justified comparative analysis results showing that the current test and the proposed one are equivalent.
|
to an approved test procedure
for the immediate packaging of the active substance or the finished product
Appropriate validation studies shall have been performed in accordance with the relevant guidelines and show that the updated test procedure is at least equivalent to the former test procedure.
The method of analysis shall remain the same (e.g. a change in column length or temperature, but not a different type of column or method).
Any new test method shall not concern a novel non-standard technique or a standard technique used in a novel way.
Amendment of the relevant section(s) of the dossier, including a description of the analytical methodology and a summary of validation data.
Comparative validation results or if justified comparative analysis results showing that the current test and the proposed one are equivalent.
|
to an approved test procedure for an in-process test
for active substance;
for the finished product
The test method shall not be a biological, immunological or immunochemical method, or a method using a biological reagent for a biological active substance.
Appropriate validation studies shall have been performed in accordance with the relevant guidelines and show that the updated test procedure is at least equivalent to the former test procedure.
There shall be no changes of the total impurity limits; no new unqualified impurities shall be detected.
The method of analysis shall remain the same (e.g. a change in column length or temperature, but not a different type of column or method).
Amendment of the relevant section(s) of the dossier.
|
in the manufacturing process of an active substance
The change shall not be applicable to a biological or immunological active substance.
The change shall not be a change in the geographical source, manufacturing route or production for a herbal veterinary medicinal substance.
The change shall not provoke an adverse change in qualitative and quantitative impurity profile or in physico-chemical properties.
The synthetic route remains the same, i.e. intermediates remain the same and there are no new reagents, catalysts or solvents used in the process.
The specifications of the active substance or intermediates are unchanged.
The change shall not refer to the restricted part of an ASMF.
Amendment of the relevant section(s) of the dossier.
Batch analysis data (in a comparative tabulated format) of at least two batches (minimum pilot scale) manufactured in accordance with the currently approved and proposed process.
|
in synthesis or recovery of a non-pharmacopoeial excipient (when described in the dossier) or a novel excipient
The excipients and all intermediates, reagents, catalysts, solvents or in-process controls shall still conform to the approved specifications (e.g. qualitative and quantitative impurity profile). Adjuvants and preservatives shall be excluded from the scope of this entry. Synthetic routes and specifications shall be identical, and there shall be no change in physico-chemical properties. | Amendment of the relevant section(s) of the dossier for batch data, comparative data, and specification, as appropriate.
|
to an in-process limit range for the finished product
The change shall not be the result of unexpected events arising during manufacture or because of stability concerns.
The change shall concern an in-process test, which is also part of the finished product specification at release, and the new in-process limit range shall be within the approved release limit.
Amendment of the relevant section(s) of the dossier. Comparative table of former and new in-process limits.
|
to an approved change management protocol of the active substance that does not change the strategy defined in the protocol
The intermediates, reagents, catalysts or solvents used in the process shall remain the same. The active substance and all intermediates, reagents, catalysts or solvents shall still conform to the approved specifications. There shall be no adverse change in qualitative and quantitative impurity profile or in physico-chemical properties. The change shall not refer to the restricted part of an ASMF.
The changes shall be within the range of currently approved limits.
In case of biological veterinary medicinal products, this change shall be only possible if comparability is not required.
Changes in the geographical source, manufacturing route or production of a herbal substance or herbal preparation of a herbal veterinary medicinal product shall be excluded.
Amendment of the relevant section(s) of the dossier.
|
to production equipment (when described in the dossier) including processes related to the equipment
The change shall not result in any changes or modifications of the production process or quality of the product. | Amendment of the relevant section(s) of the dossier.
|
to an approved test procedure
of a measuring or administration device
Appropriate validation studies shall have been performed in accordance with the relevant guidelines and show that the updated test procedure is at least equivalent to the former test procedure.
The method of analysis shall remain the same.
Amendment of the relevant section(s) of the dossier, including a description of the analytical methodology and a summary of validation data.
Comparative validation results or if justified comparative analysis results showing that the current test and the proposed one are equivalent.
|
in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product
The change relates only to an immediate release solid oral dosage form/oral solution and the veterinary medicinal product concerned is not a biological/immunological or herbal veterinary medicinal product.
The manufacturing steps remain the same. The finished product / intermediates / in-process materials used in the manufacture of the finished product shall still conform to the approved specifications. No adverse change in qualitative and quantitative impurity profile or in physico-chemical properties. The new process shall lead to an identica product regarding all aspects of quality, safety and efficacy. Relevant stability studies in accordance with the relevant guidelines shall have been started with at least one pilot scale or industrial scale batch and at least 3 months stability data shall be at the disposal of the applicant.
Amendment of the relevant section(s) of the dossier.
For solid dosage forms: dissolution profile data of one representative production batch and comparative data of the last three batches from the previous process; data on the next two full production batches shall be available on request or reported if outside specification (with proposed action).
Justification for not submitting a new bioequivalence study in accordance with the relevant guidance on Bioavailability/Bioequivalence.
Batch analysis data (in a comparative tabulated format) on a minimum of one batch manufactured in accordance to both the currently approved and the proposed process.’
entry 13 is replaced by the following:
‘13 | Changes to a test procedure (including replacement or addition): |
The active substance/finished product shall not be biological or immunological.
Appropriate validation studies have been performed in accordance with the relevant guidelines and show that the updated test procedure is at least equivalent to the former test procedure.
The new test method shall not concern a novel non-standard technique or a standard technique used in a novel way.
Amendment of the relevant section(s) of the dossier and comparative validation data, as appropriate.
In the absence of comparative validation data, if justified, comparative analysis results showing that the current test and the proposed one are equivalent. This requirement is not applicable in case of an addition of a new test procedure.’
|
for a reagent used in the manufacturing process of the active substance but which does not have a significant effect on the overall quality of the active substance
There shall be no changes to the total impurity limits; no new unqualified impurities shall be detected. The method of analysis shall remain the same (e.g. a change in column length or temperature, but not a different type of column or method). |
|
for the immediate packaging of the active substance
entry 14 is replaced by the following: